Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15	AUG 27	USPATOLD now available on STN
NEWS 16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18	SEP 13	FORIS renamed to SOFIS
NEWS 19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24	OCT 19	BEILSTEIN updated with new compounds
NEWS 25	NOV 15	Derwent Indian patent publication number format enhanced

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:07:02 ON 16 NOV 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:07:09 ON 16 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 NOV 2007 HIGHEST RN 953991-83-8
DICTIONARY FILE UPDATES: 15 NOV 2007 HIGHEST RN 953991-83-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10567310 371.str





chain nodes :
14 15 16 17 19 20 21 22 25 26 27 28 29 30 31 32
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
5-8 7-25 7-26 9-31 9-32 10-29 10-30 11-14 12-27 12-28 14-15 15-16 15-19
16-17 20-21 20-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
5-8 7-8 7-12 8-9 9-10 10-11 11-12 11-14 14-15 15-16 15-19 16-17 20-21
20-22
exact bonds :
7-25 7-26 9-31 9-32 10-29 10-30 12-27 12-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 7 :

G1:Cb,Ak

G2:H,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 24:Atom
25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS

L1 STR



G1 Cb,Ak
G2 H,O

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 16:08:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 618324 TO ITERATE

100.0% PROCESSED 618324 ITERATIONS 48 ANSWERS
SEARCH TIME: 00.00.06

L2 48 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.00	173.21

FILE 'CAPLUS' ENTERED AT 16:08:53 ON 16 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Nov 2007 VOL 147 ISS 22
FILE LAST UPDATED: 15 Nov 2007 (20071115/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2 full
L3 7 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1257556 CAPLUS Full-text
DOCUMENT NUMBER: 147:180509
TITLE: Estimation of phospholipophilicity of 1-[3-(arylpiperazin-1-yl)-propyl]-pyrrolidin-2-one derivatives on immobilized artificial membrane stationary phase and its correlation with biological data
AUTHOR(S): Kulig, Katarzyna; Malawska, Barbara
CORPORATE SOURCE: Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Medical College Jagiellonian University, Krakow, 30-688, Pol.
SOURCE: Biomedical Chromatography (2006), 20(11), 1129-1135
CODEN: BICHE2; ISSN: 0269-3879
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A mol. library containing 42 1-[3-(arylpiperazin-1-yl)-propyl]-pyrrolidin-2-one derivs. has been designed and synthesized. The phospholipophilicity of the obtained compds. has been determined using immobilized artificial membrane high-performance liquid chromatog. (IAM-HPLC). The performed anal. allowed the calcn. of log kwe values for each of the tested compds. Exptl. phospholipophilicity data (log kwe) has been compared with the affinity of the tested compds. to α2-adrenoceptors. Performed quant. structure-activity relationship studies indicated that, for the tested compds., there are dependences between affinity for α2-adrenoceptors and their log kwe values. The obtained results confirmed that the applied chromatog. IAM-HPLC method could be useful in fast characterization of the phospholipophilicity of structurally closely related compds. as well as for larger series of compds., such as drug candidates. It could also be used as a tool for further research into this group of compds.
IT 944402-80-6
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phospholipophilicity of 1-[3-(arylpiperazin-1-yl)-propyl]-pyrrolidin-2-one derivs. dependence on affinity for α2-adrenoceptors for drug discovery)
RN 944402-80-6 CAPLUS
CN 2-Pyrrolidinone, 1-[3-[4-(2-acetylphenyl)-1-piperazinyl]-2-methoxypropyl]- (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1330455 CAPLUS Full-text
DOCUMENT NUMBER: 144:51611
TITLE: Preparation of disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
INVENTOR(S): Sonesson, Clas; Swanson, Lars; Waters, Nicholas
PATENT ASSIGNEE(S): A. Carlsson Research AB, Swed.
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005121087	A1	20051222	WO 2005-EP6147	20050608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005251906	A1	20051222	AU 2005-251906	20050608
AU 2005251909	A1	20051222	AU 2005-251909	20050608
CA 2569840	A1	20051222	CA 2005-2569840	20050608
CA 2569843	A1	20051222	CA 2005-2569843	20050608
WO 2005121088	A1	20051222	WO 2005-EP6154	20050608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,				

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1768958	A1	20070404	EP 2005-746589		20050608
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
EP 1773772	A1	20070418	EP 2005-760618		20050608
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 1997630	A	20070711	CN 2005-80023206		20050608
CN 1997631	A	20070711	CN 2005-80023251		20050608
US 2007179185	A1	20070802	US 2006-567925		20061207
US 2007149542	A1	20070628	US 2006-608313		20061208
IN 2007DN00067	A	20070803	IN 2007-DN67		20070102
NO 2007000124	A	20070308	NO 2007-124		20070108
KR 2007050425	A	20070515	KR 2007-700513		20070108
PRIORITY APPLN. INFO.:			SE 2004-1464	A	20040608
			US 2004-577953P	P	20040608
			SE 2004-3142	A	20041220
			US 2004-637530P	P	20041220
			WO 2005-EP6147	W	20050608
			WO 2005-EP6154	W	20050608

OTHER SOURCE(S): CASREACT 144:51611; MARPAT 144:51611

GI



I

AB Title compds. I [X = N, CH; R1 = OSO2CF3, OSO2CH3, NHSO2CH3, etc.; R2 = CN, CF3, OH, NH2, etc.; R3 = alkyl, allyl, CH2CH2OCH3, etc.] are prepared For instance, 4-[2-fluoro-3-(methylsulfonyl)phenyl]-1-propylpiperidine (II) is prepared in 5 steps from 4-[2-fluoro-3-(methylthio)phenyl]-1,2,3,6-tetrahydropyridine and 1-iodopropane. II had ED50 = 28 μmol/kg on increase of DOPAC (3,4-dihydroxyphenylacetic acid) in the rat striatum. I have therapeutic effects against disorders in the central nervous system.

IT 871355-49-6P, 1-[3-[4-(2-Methoxyethyl)piperazin-1-yl]-2-methylphenyl]ethanone 871355-53-2P, 1-[2-Fluoro-3-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]ethanone 871355-57-6P, 2-Acetyl-6-[4-(2-methoxyethyl)piperazin-1-yl]benzonitrile 871355-61-2P, 1-[2-Chloro-3-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]ethanone 871357-07-2P, 2,2,2-Trifluoro-1-[3-[4-(2-methoxyethyl)piperazin-1-yl]-2-methylphenyl]ethanone 871357-11-8P, 2,2,2-Trifluoro-1-[2-fluoro-3-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]ethanone 871357-15-2P, 2-[4-(2-Methoxyethyl)piperazin-1-yl]-6-(trifluoroacetyl)benzonitrile 871357-20-9P,

1-[2-Chloro-3-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-2,2,2-trifluoroethanone
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of disubstituted phenylpiperidines/piperazines as modulators of
dopamine neurotransmission)

RN 871355-49-6 CAPLUS
CN Ethanone, 1-[3-[4-(2-methoxyethyl)-1-piperazinyl]-2-methylphenyl]- (CA INDEX NAME)



RN 871355-53-2 CAPLUS
CN Ethanone, 1-[2-fluoro-3-[4-(2-methoxyethyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 871355-57-6 CAPLUS
CN Benzonitrile, 2-acetyl-6-[4-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 871355-61-2 CAPLUS
CN Ethanone, 1-[2-chloro-3-[4-(2-methoxyethyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 871357-07-2 CAPLUS
CN Ethanone, 2,2,2-trifluoro-1-[3-[4-(2-methoxyethyl)-1-piperazinyl]-2-methylphenyl]- (CA INDEX NAME)



RN 871357-11-8 CAPLUS
CN Ethanone, 2,2,2-trifluoro-1-[2-fluoro-3-[4-(2-methoxyethyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 871357-15-2 CAPLUS
CN Benzonitrile, 2-[4-(2-methoxyethyl)-1-piperazinyl]-6-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 871357-20-9 CAPLUS
CN Ethanone, 1-[2-chloro-3-[4-(2-methoxyethyl)-1-piperazinyl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1078248 CAPLUS Full-text
DOCUMENT NUMBER: 143:360127
TITLE: Preparation of diagnostic and therapeutic alkyl piperidine/piperazine compounds for neuron imaging and treating neurodegenerative disease
INVENTOR(S): Elmaleh, David R.; Songwoon, Choi; Fishman, Alan J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005222166	A1	20051006	US 2004-814118	20040331
PRIORITY APPLN. INFO.:			US 2004-814118	20040331

OTHER SOURCE(S): CASREACT 143:360127; MARPAT 143:360127
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Piperidine or piperazine compds. useful for treating neurodegenerative diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons are provided. The compds. are characterized by the formulas I-V : m = 1-6; X, Y, Z1, Z2, and Z3 = H, halo, haloalkyl, alkyl, aryl, (C1-C6) alkoxy, N-alkyl,(C2-C6) acyloxy, N-alkylene, -SH, -SR, wherein R is from the same group as R1 and R2, NH2, NO, CN, OH, COOR6, C(O)NR5R4, NR3R2, or S(O)kR1 wherein k = 1 or 2 and R1 to R6 = H or (C1-C6)alkyl; R1 and R2 = H, (C1-C6) alkyl, hydroxyalkyl or mercaptoalkyl, -COOR1, CN, (C1-C6)alkenyl, (C2-C6)alkynyl, or (un)substituted 1,2,4-oxadiazol-5-yl; R7= H, O or Ph; R8 = H, Ph, halophenyl, nitrophenyl, pyridyl, piperonyl or sulfoxonitrophenyl; W = O or S; T = NH2 or C1-C6 aminoalkyl; A = N or C; T= C1-C6 alkyl or sulfonyl; Q=NH2 or C1-C6 amino alkyl.

IT 728946-06-3P, 1-[4-[4-[4-[Bis(4-fluorophenyl)methoxy]butyl]piperazin-1-yl]phenyl]ethanone oxalate
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of diagnostic and therapeutic alkyl piperidine/piperazine compds. for neuron imaging and treating neurodegenerative disease)

RN 728946-06-3 CAPLUS

CN Ethanone, 1-[4-[4-[4-[bis(4-fluorophenyl)methoxy]butyl]-1-piperazinyl]phenyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 728946-05-2
CMF C29 H32 F2 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:8311 CAPLUS Full-text
DOCUMENT NUMBER: 142:116228
TITLE: Piperazine-based radiation curing sensitizers
INVENTOR(S): Davidson, Robert Stephen; Herlihy, Shaun Lawrence; Rowatt, Brian
PATENT ASSIGNEE(S): Sun Chemical Limited, UK
SOURCE: Brit. UK Pat. Appl., 28 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2403478	A	20050105	GB 2003-15774	20030704
WO 2005007637	A1	20050127	WO 2004-US21370	20040702

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1660470 A1 20060531 EP 2004-777489 20040702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

CN 1845912 A 20061011 CN 2004-80025346 20040702

US 2007066700 A1 20070322 US 2006-567310 20061129

PRIORITY APPLN. INFO.: GB 2003-15774 A 20030704
WO 2004-US21370 W 20040702

OTHER SOURCE(S): MARPAT 142:116228

GI



I

AB A piperazine-based compound of formula I and esters thereof are useful as sensitizers for use in radiation-curable compns., wherein: R1 represents a Me group, an Et group, a C5 or C6 cycloalkyl group or a C6 - C10 aryl group, said aryl group being unsubstituted or being substituted by at least one C1 - C4 alkyl or alkoxy group; Z represents a C6 - C10 arylene group or a group of formula --(CHR4)n--, where R4 represents a hydrogen atom, a hydroxy group or a C1 - C4 alkyl group, and n is a number from 0 to 6; Y represents a carbonyl group or a --CH2-- group, provided that R4 represents a hydroxy group when Y represents a --CH2-- group; Q represents a residue of a mono- or poly-hydroxy compound having from 1 to 6 hydroxy groups; and x is a number from 1 to 6.

IT 819866-13-2P
RL: PRP (Properties); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(piperazine-based radiation curing sensitizers)

RN 819866-13-2 CAPLUS

CN Ethanone, 1,1'-[[2-[[3-[4-(4-acetylphenyl)-1-piperazinyl]-2-hydroxypropoxy]methyl]-2-ethyl-1,3-propanediyl]bis[oxy(2-hydroxy-3,1-propanediyl)-4,1-piperazinediyl-4,1-phenylene]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:606436 CAPLUS Full-text

DOCUMENT NUMBER: 141:157135

TITLE: Preparation of piperidine and piperazine derivatives with dopaminergic neurotransmitter system activity for diagnostic and therapeutic uses

INVENTOR(S): Elmaleh, David R.; Choi, Sangwoon; Fishman, Alan J.

PATENT ASSIGNEE(S): The General Hospital Corporation, USA

SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063150	A2	20040729	WO 2003-US41731	20031231
WO 2004063150	A3	20050602		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003300147	A1	20040810	AU 2003-300147	20031231
PRIORITY APPLN. INFO.:			US 2003-437885P	P 20030106
			WO 2003-US41731	W 20031231

OTHER SOURCE(S): MARPAT 141:157135
GI



I

AB Piperazine derivs., such as I [R7 = H, Ph, :O; R8 = H, Ph, COMe, COPh, halophenyl, nitrophenyl, nitrophenylsulfonyl, piperonyl], were prepared for use in treating neurodegenerative diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons. Thus, piperazine derivative II (R7 = R8 = H) was prepared via an amination reaction with 30% yield of (F-4-C6H4)2CHO(CH2)4Cl and piperazine using K2CO3 in DMF. The prepared piperazines were assayed. for binding affinities at the DA, 5-HT and NE transporters labeled with [125I]RTI-55.

IT 728946-05-2P 728946-06-3P
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine and piperazine derivs. with dopaminergic neurotransmitter system activity for diagnostic and therapeutic uses)

RN 728946-05-2 CAPLUS
CN Ethanone, 1-[4-[4-[4-[bis(4-fluorophenyl)methoxy]butyl]-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 728946-06-3 CAPLUS
CN Ethanone, 1-[4-[4-[4-[bis(4-fluorophenyl)methoxy]butyl]-1-piperazinyl]phenyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 728946-05-2
CMF C29 H32 F2 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:832759 CAPLUS Full-text
DOCUMENT NUMBER: 137:353062
TITLE: Preparation of 2-iminopyrrolidine derivatives as thrombin receptor antagonists
INVENTOR(S): Suzuki, Shuichi; Kotake, Makoto; Miyamoto, Mitsuaki; Kawahara, Tetsuya; Kajiwara, Akiharu; Hishinuma, Ieharu; Okano, Kazuo; Miyazawa, Syuhei; Clark, Richard; Ozaki, Fumihiro; Sato, Nobuaki; Shinoda, Masanobu; Kamada, Atsushi; Tsukada, Itaru; Matsuura, Fumiyoshi; Naoe, Yoshimitsu; Terauchi, Taro; Oohashi, Yoshiaki; Ito, Osamu; Tanaka, Hiroshi; Musya, Takashi; Kogushi, Motoji; Kawada, Tsutomu; Matsuoka, Toshiyuki; Kobayashi, Hiroko; Chiba, Kenichi; Kimura, Akifumi; Ono, Naoto

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 948 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085855	A1	20021031	WO 2002-JP3961	20020419
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2446924	A1	20021031	CA 2002-2446924	20020419
AU 2002255269	A1	20021105	AU 2002-255269	20020419
AU 2002255269	B2	20070315		
EP 1391451	A1	20040225	EP 2002-724628	20020419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002008985	A	20040309	BR 2002-8985	20020419
CN 1503784	A	20040609	CN 2002-808565	20020419
HU 2004000467	A2	20050228	HU 2004-467	20020419
EP 1614680	A2	20060111	EP 2005-22069	20020419
EP 1614680	A3	20060201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
CN 1733725	A	20060215	CN 2005-10080404	20020419
RU 2270192	C2	20060220	RU 2003-133664	20020419
CN 1754880	A	20060405	CN 2005-10080403	20020419
JP 3795458	B2	20060712	JP 2002-583382	20020419
NZ 528820	A	20070126	NZ 2002-528820	20020419
NO 2003004632	A	20031219	NO 2003-4632	20031016
MX 2003PA09497	A	20040524	MX 2003-PA9497	20031016
ZA 2003008064	A	20050207	ZA 2003-8064	20031016
IN 2003DN01719	A	20051014	IN 2003-DN1719	20031020
US 2005004204	A1	20050106	US 2004-475188	20040609
US 7244730	B2	20070717		
AU 2005202135	A1	20050609	AU 2005-202135	20050517
US 2005245592	A1	20051103	US 2005-158941	20050622
JP 2006206595	A	20060810	JP 2006-41270	20060217
JP 2006225393	A	20060831	JP 2006-41255	20060217

PRIORITY APPLN. INFO.:	JP 2001-121829	A	20010419
	JP 2001-269422	A	20010905
	CN 2002-808565	A3	20020419
	EP 2002-724628	A3	20020419
	JP 2002-583382	A3	20020419
	WO 2002-JP3961	W	20020419
	US 2004-475188	A1	20040609

OTHER SOURCE(S): MARPAT 137:353062
GI



I



II

AB 2-Iminopyrrolidine derivs. including 2,3-dihydro-1H-isoindole and 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine represented by the general formula (I) or salts thereof [wherein B = (un)substituted aromatic hydrocarbon or aromatic heterocyclic ring optionally containing 1 or 2 N atom(s); R101, R102, R103 = H, cyano, halo, each (un)substituted C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, acyl, CO2H, CONH2, C1-6 alkoxycarbonyl, C1-6 alkylaminocarbonyl, HO, C1-6 alkoxy, C3-8 cycloalkyloxy, NH2, C1-6 alkylamino, C3-8 cycloalkylamino, acylamino, ureido, sulfonylamino, sulfonyl, SO2NH2, or C3-8 cycloalkyl, etc.; Y1 = a single bond, (CH2)m, each (un)substituted CH, CH2, NH, CONH, or SO2NH, CH2CO, SO, SO2, CO (wherein m = an integer of 1-3); Y2 = a single bond, O, N, (CH2)m, each (un)substituted CH, CH2, or C(:NOH), CO, SO, SO2; Ar = H, (un)substituted Ph] are prepared These compds. are thrombin receptor antagonists, in particular thrombin PAR1 receptor antagonists and are useful as blood platelet aggregation inhibitors and proliferation inhibitors of smooth muscle cell, endothelial cell, fibroblast, kidney cell, osteosarcoma cell, muscle cell, cancer cell, and/or glial cell and for the treatment and/or prevention of thrombosis, vascular restenosis, deep vein thrombosis, lung embolism, cerebral infarction, heart disease, disseminated intravascular coagulation syndrome, hypertension, inflammation, rheumatism, asthma, glomerulonephritis, osteoporosis, nerve disease, and/or malignant tumor. Thus, [6-[(1-imino-1,3-dihydroisoindol-2-yl)acetyl]-2,3- dihydrobenz[1,4]oxazin-4-yl]acetonitrile derivative (II) in vitro showed IC50 of 0.017 μM for inhibiting the binding of [3H]Ala-(4-fluoro)Phe-Arg- (cyclohexyl)Ala-homoArg-Tyr-NH2 to thrombin receptor of human blood platelet, that of 0.29 μM for inhibiting the human blood platelet aggregation induced by thrombin, and that of 0.0061 μM for inhibiting the proliferation of rat smooth cell.

IT 474544-64-4P 474623-38-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydroisoindole and dihydro-5H-pyrrolo[3,4-b]pyridine derivs. as thrombin receptor antagonists and remedies and/or preventives for diseases)

RN 474544-64-4 CAPLUS

CN 1H-Isoindole-5-carboxamide, 2-[2-[3-(1,1-dimethylethyl)-4-methoxy-5-[4-(methoxyacetyl)-1-piperazinyl]phenyl]-2-oxoethyl]-6-ethoxy-2,3-dihydro-3-imino-N-methyl-, monohydrobromide (9CI) (CA INDEX NAME)



RN 474623-38-6 CAPLUS
CN Piperazine, 1-[5-[(5,6-diethoxy-7-fluoro-1,3-dihydro-1-imino-2H-isoindol-2-yl)acetyl]-3-(1,1-dimethylethyl)-2-methoxyphenyl]-4-(methoxyacetyl)-, monohydrobromide (9CI) (CA INDEX NAME)



IT 474554-77-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydroisoindole and dihydro-5H-pyrrolo[3,4-b]pyridine derivs. as thrombin receptor antagonists and remedies and/or preventives for diseases)
RN 474554-77-3 CAPLUS
CN Piperazine, 1-[5-(bromoacetyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl]-4-(ethoxyacetyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 100 THERE ARE 100 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:246566 CAPLUS Full-text
DOCUMENT NUMBER: 134:280864
TITLE: Preparation of 6-azauracil derivatives as thyroid receptor ligands
INVENTOR(S): Dow, Robert Lee; Chiang, Yuan-Ching Phoebe; Estep, Kimberly Gail
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 153 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1088819	A2	20010404	EP 2000-308112	20000918
EP 1088819	A3	20010411		
EP 1088819	B1	20050615		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 297905	T	20050715	AT 2000-308112	20000918
PT 1088819	T	20050930	PT 2000-308112	20000918
ES 2240017	T3	20051016	ES 2000-308112	20000918
JP 2001114768	A	20010424	JP 2000-282882	20000919
JP 3763565	B2	20060405		
US 6787652	B1	20040907	US 2000-671668	20000927
CA 2321380	A1	20010330	CA 2000-2321380	20000928
CA 2321380	C	20060530		
BR 2000004539	A	20010417	BR 2000-4539	20000929
MX 2000PA09641	A	20020201	MX 2000-PA9641	20001002
US 2004157844	A1	20040812	US 2004-763451	20040123
US 6930107	B2	20050816		

PRIORITY APPLN. INFO.: US 1999-156842P P 19990930
US 2000-671668 A1 20000927
OTHER SOURCE(S): MARPAT 134:280864
GI



I

AB Title compds. [I; W = O, S, SO, SO2, NR30, CO, CH:CH, CH2, CHF, CF2, CH(OH); R1, R2 = H, halo, alkyl, cyano, OR12, CF3; R3 = H, halo, cyano, NO2, (substituted) alkyl, etc.; R4 = CR14R15R16, CONR19R20, aryl, heteroaryl, etc.; R3R4 = (CH2)b, Q(CH2)c, etc.; b = 3-7; c = 2-6; R5 = OR23; R4R5 = CR31:CR32NH,

CR31:CR32S, etc.; R7 = H, alkyl, haloalkyl, (CH2)nCO2R9; n = 0-3; R8 = H, alkyl, CO2R9, CONR10R11; R9 = (substituted) alkyl, alkenyl, dialkenyl, cycloalkyl, aryl, heterocyclyl; R10, R11 = H, (substituted) alkyl, cycloalkyl, alkenyl, heterocyclyl; R10R11 = heterocyclyl; R12 = H, (substituted) alkyl; R14 = H, alkyl, OR34; R15 = H, alkyl; R14R15 = O; R16 = H, (substituted) alkyl, alkylcycloalkyl, alkylaryl, alkylheterocyclyl; R19, R20 = H, (substituted) alkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, etc.; R23 = H, (substituted) alkyl, COR24; R24 = H, (substituted) alkyl, alkenyl, cycloalkyl, aryl, heteroaryl; R30 = H, (substituted) alkyl, alkenyl, cycloalkyl, COR31, etc.; R31 = H, (substituted) alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, etc.; R32 = H, (substituted) alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl; R34 = (substituted) aryl, heterocyclyl, alkyl, alkenyl, cycloalkyl], were prepared for treatment of obesity, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmia, glaucoma and heart failure (no data). Thus, [[[4-(3-bromo-4-methoxyphenoxy)-3,5-dimethylphenyl]hydrazono]cyanoacetyl]carbamic acid Et ester (preparation given) was heated with KOAc in HOAc at 120° for 5 h to give 2-[4-(3-bromo-4-methoxyphenoxy)-3,5-dimethylphenyl]-3,5-dioxo-2,3,4,5- tetrahydro-1,2,4-triazine-6-carbonitrile.

IT 332933-26-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azauracil derivs. as thyroid receptor ligands)

RN 332933-26-3 CAPLUS

CN 1,2,4-Triazine-6-carboxylic acid, 2-[4-(3-bromo-4-methoxyphenoxy)-3,5-dimethylphenyl]-2,3,4,5-tetrahydro-3,5-dioxo-, 2-[4-(4-acetylphenyl)-1-piperazinyl]ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

OMe

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	38.30	211.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE -5.46 -5.46

FILE 'REGISTRY' ENTERED AT 16:10:31 ON 16 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 NOV 2007 HIGHEST RN 953991-83-8
DICTIONARY FILE UPDATES: 15 NOV 2007 HIGHEST RN 953991-83-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10567310noZ.str





chain nodes :
14 15 16 18 19 20 21 24 25 26 27 28 29 30 31
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
5-8 7-24 7-25 9-30 9-31 10-28 10-29 11-14 12-26 12-27 14-18 14-15 15-16

19-20 19-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
5-8 7-8 7-12 8-9 9-10 10-11 11-12 11-14 14-18 14-15 15-16 19-20 19-21

exact bonds :
7-24 7-25 9-30 9-31 10-28 10-29 12-26 12-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 7 :

G1:Cb,Ak

G2:H,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:CLASS 15:CLASS 16:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 23:Atom 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS

L4   STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4   STR



G1 Cb,Ak
G2 H,O

Structure attributes must be viewed using STN Express query preparation.

=> s l4 full
FULL SEARCH INITIATED 16:14:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   186985 TO ITERATE

100.0% PROCESSED   186985 ITERATIONS   0 ANSWERS

SEARCH TIME: 00.00.03

L5 0 SEA SSS FUL L4

=> file re
'RE' IS AN AMBIGUOUS FILE OR CLUSTER NAME
REACTION - Reactions Cluster
RESEARCH - Research Cluster
REGISTRY - The CAS Registry File of substances
ENTER FILE OR CLUSTER NAME (IGNORE):file reg
'FILE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):.

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	176.60	388.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.46

FILE 'REGISTRY' ENTERED AT 16:16:52 ON 16 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 NOV 2007 HIGHEST RN 953991-83-8
DICTIONARY FILE UPDATES: 15 NOV 2007 HIGHEST RN 953991-83-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	388.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.46

FILE 'REGISTRY' ENTERED AT 16:16:54 ON 16 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 NOV 2007 HIGHEST RN 953991-83-8
DICTIONARY FILE UPDATES: 15 NOV 2007 HIGHEST RN 953991-83-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10567310noY.str





chain nodes :
14 15 17 18 19 22 23 24 25 26 27 28 29
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
5-8 7-22 7-23 9-28 9-29 10-26 10-27 11-14 12-24 12-25 14-15 17-18 17-19

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
5-8 7-8 7-12 8-9 9-10 10-11 11-12 11-14 14-15 17-18 17-19
exact bonds :

7-22 7-23 9-28 9-29 10-26 10-27 12-24 12-25
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 7 :

G1:Cb,Ak

G2:H,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:CLASS 15:CLASS 17:CLASS 18:CLASS 19:CLASS 21:Atom
22:CLASS 23:CLASS 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR



G1 Cb,Ak
G2 H,O

Structure attributes must be viewed using STN Express query preparation.

=> s l6 full
FULL SEARCH INITIATED 16:17:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1382 TO ITERATE

100.0% PROCESSED 1382 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L7 0 SEA SSS FUL L6

=> d his

(FILE 'HOME' ENTERED AT 16:07:02 ON 16 NOV 2007)

```
     FILE 'REGISTRY' ENTERED AT 16:07:09 ON 16 NOV 2007
L1              STRUCTURE UPLOADED
L2           48 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 16:08:53 ON 16 NOV 2007
L3            7 S L2 FULL

     FILE 'REGISTRY' ENTERED AT 16:10:31 ON 16 NOV 2007
L4              STRUCTURE UPLOADED
L5            0 S L4 FULL

     FILE 'REGISTRY' ENTERED AT 16:16:52 ON 16 NOV 2007

     FILE 'REGISTRY' ENTERED AT 16:16:54 ON 16 NOV 2007
L6              STRUCTURE UPLOADED
L7            0 S L6 FULL

=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 174.35     562.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00      -5.46

STN INTERNATIONAL LOGOFF AT 16:20:37 ON 16 NOV 2007
```